Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma

被引:16
|
作者
Boscolo-Rizzo, Paolo [1 ]
Muzzi, Enrico [2 ]
Trabalzini, Franco [3 ]
Gava, Alessandro [4 ]
Stellin, Marco [1 ]
Da Mosto, Maria Cristina [1 ]
机构
[1] Univ Padua, Dept Med & Surg Special, Reg Ctr Head & Neck Canc, Sch Med,Treviso Reg Hosp, I-31100 Treviso, Italy
[2] Univ Padua, Dept Med & Surg Special, Serv Audiol & Phoniatr, Sch Med,Treviso Reg Hosp, I-31100 Treviso, Italy
[3] Siena Univ Hosp, Dept Sense Organs Otol & Skull, Base Surg Unit, Siena, Italy
[4] Treviso Reg Hosp, Dept Radiat Oncol, I-31100 Treviso, Italy
关键词
Aged; Chemotherapy; Combined modality therapy; Functional outcome; Head and neck cancer; Radiotherapy; ADVANCED LARYNGEAL-CANCER; PHASE-III TRIAL; OF-THE-ART; HUMAN-PAPILLOMAVIRUS; CHEMOTHERAPY; CHEMORADIATION; SURVIVAL;
D O I
10.1007/s00405-011-1489-y
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The aim of the present investigation is to evaluate the outcome after induction chemotherapy and concurrent multi-drug chemoradiotherapy (IC/CCRT) with or without post-chemoradiation neck dissection in medically fit elderly patients with loco-regionally advanced head and neck squamous cell carcinoma (HNSCC). Retrospective study including 44 elderly patients (median age 71 years; range 66-77 years) with previously untreated, inoperable, histologically proven non-metastatic stage III or IV HNSCC. Following one cycle of IC, two cycles of cis-platinum and 5-fluorouracil CCRT with conventional fractionated radiotherapy up to a dose of 66-70 Gy were administrated. A neck dissection was recommended for patients with node metastasis larger than 3 cm regardless of the response to therapy and for patients who had suspected persistent neck disease 8-12 weeks after completing treatment. Salvage surgery was considered for histologically proven persistent or recurrent tumor in the primary site. Time-to-event data were described using Kaplan-Meier actuarial curves. Overall, 37 patients (84.1%) completed the planned treatment. There were no cases of treatment-related deaths. Twenty-nine patients (65.9%) developed severe toxicities with grade 4 toxicity accounting for 22.7%. The median follow-up time in survivors was 41 months. Three-year overall survival, progression-free survival, and functional progression-free survival estimates were 70.9, 67.0, and 57.3%, respectively. In selected medically fit elderly patients with loco-regionally advanced HNSCC, cis-platinum-based chemoradiotherapy can be successfully applied, with moderate adverse events, in attempt to preserve a functional upper aerodigestive tract.
引用
收藏
页码:1349 / 1355
页数:7
相关论文
共 50 条
  • [11] Postoperative adjuvant therapy for patients with loco-regionally advanced oral squamous cell carcinoma who are at high risk of recurrence
    Yanamoto, S.
    Denda, Y.
    Ota, Y.
    Hasegawa, T.
    Akashi, M.
    Okura, M.
    Yamada, S. -I.
    Kurita, H.
    Yamakawa, N.
    Kirita, T.
    Ueda, M.
    Umeda, M.
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2020, 49 (07) : 848 - 853
  • [12] Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy
    Boscolo-Rizzo, P.
    Gava, A.
    Marchiori, C.
    Baggio, V.
    Da Mosto, M. C.
    ANNALS OF ONCOLOGY, 2011, 22 (08) : 1894 - 1901
  • [13] Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation
    Poole, ME
    Sailer, SL
    Rosenman, JG
    Tepper, JE
    Weissler, MC
    Shockley, WW
    Yarbrough, WG
    Pillsbury, HC
    Schell, MJ
    Bernard, SA
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2001, 127 (12) : 1446 - 1450
  • [14] Concomitant chemoradiotherapy in advanced squamous cell carcinoma of the head and neck
    Karlsruher, J
    Samith, A
    Krause, H
    1ST WORLD CONGRESS ON HEAD AND NECK ONCOLOGY, 1998, : 933 - 936
  • [15] Concurrent cetuximab, cisplatin, and radiotherapy (RT) for loco-regionally advanced squamous cell carcinoma of the head and neck (SCCHN): Updated results of a novel combined modality paradigm.
    Su, YB
    Kraus, DH
    Zelefsky, MJ
    Lis, E
    Nolden, SL
    Herman, K
    Sedarati, F
    Shaha, AR
    Shah, JP
    Pfister, DG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 507S - 507S
  • [16] Management of advanced head and neck squamous cell carcinoma in elderly patients
    Awada, Ahmad
    Junior, Gilberto de Castro
    CURRENT OPINION IN ONCOLOGY, 2006, 18 (03) : 225 - 227
  • [17] Chemoradiotherapy in advanced squamous head and neck carcinoma
    Rovirosa, A
    1ST WORLD CONGRESS ON HEAD AND NECK ONCOLOGY, 1998, : 901 - 904
  • [18] Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic
    Kelly K. Curtis
    Helen J. Ross
    Ashley L. Garrett
    Theresa A. Jizba
    Ajay B. Patel
    Samir H. Patel
    William W. Wong
    Michele Y. Halyard
    Stephen J. Ko
    Heidi E. Kosiorek
    Robert L. Foote
    Radiation Oncology, 11
  • [19] Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?
    Agarwal, J. P.
    Gupta, T.
    Kalyani, N.
    Budrukkar, A.
    Laskar, S. G.
    Murthy, V
    Kumar, P.
    Narohna, V
    Pai, P.
    Chaturvedi, P.
    D'cruz, A. K.
    INDIAN JOURNAL OF CANCER, 2011, 48 (02) : 148 - 153
  • [20] Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic
    Curtis, Kelly K.
    Ross, Helen J.
    Garrett, Ashley L.
    Jizba, Theresa A.
    Patel, Ajay B.
    Patel, Samir H.
    Wong, William W.
    Halyard, Michele Y.
    Ko, Stephen J.
    Kosiorek, Heidi E.
    Foote, Robert L.
    RADIATION ONCOLOGY, 2016, 11